


FIG. IA



Full length B7:

(SEQ ID NO: 2) Forward MR67 5'-GCG CTGCAG CATCTGAAGCCATGGGCC-3' (307-324)

(SEQ ID NO: 3) Backward MR68 5'-CGC GGTACC TTGCTTCTGCGGACACTG-3' (1182-1199)

Soluble B7:

(SEQ ID NO: 2) Forward MR67 5'-GCG CTGCAG CATCTGAAGCCATGGGCC-3' (307-324) Backward MR145 5'-6CGC GGTACC TTACTCCATGGGCATGTATTCCTCTTCCTCGTTATCAGGAAAATGCTGTTG-3' (1022-1042)

(SEQ ID NO: 4)

Full length CD40:

(SEQ ID NO: 5) Forward MR108 5'-6CGT AGATCT GGTCTCACCTCGCCATGGTTCG-3' (34-55)

(SEQ ID NO: 6) Backward MR112 5'-6CGT GGTACC CCACACTCCTGGGTGGGTGCAGCC-3' (882-905)

Soluble CD40:

(SEQ ID NO: 5) Forward MR108 5'-6CGT AGATCT GGTCTCACCTCGCCATGGTTCG-3' (34-55) Backward MR150 5'-6CGT GGTACC TTACTCCATGGGCATGTATTCCTCTTCCTCATCAGTCTTGTTGTGCCTGC-3' (575-596)

FIG. 2

(SEQ ID NO: 7)






FIG. 3





mab concentration (ng/ml) FIG. 5A








FIG. 5B









-•- 5D12 -•- MOPC-141 FIG. 9A




FIG. 9B

NO ADDITION

ANTI-CD40

MOPC-141

hCD40-H

hIgh